Cytokine, Chemokine, and Growth Factor Panel (95-Plex)
Use this test to identify relevant therapy targets or investigate mechanisms of disease for autoimmune disorders (e.g., RA, SLE), autoinflammatory diseases (e.g., FMF, CAPS, sJIA), chronic inflammatory diseases (e.g., IBD, psoriatic arthritis, ankylosing spondylitis, Kawasaki disease), cytokine storm syndromes (e.g., MAS, HLH, post-HSCT or CAR-T hyperinflammation), neoplastic and paraneoplastic conditions (e.g., hematologic malignancies, paraneoplastic syndromes, cancer-associated inflammation), and complex chronic conditions (e.g., fibromyalgia, ME/CFS, long COVID, post-treatment Lyme disease syndrome).
ANALYTES / BIOMARKERS
6Ckine (CCL21), APRIL, BAFF, BCA-1 (CXCL13), CCL28, CTACK (CCL27), EGF, ENA-78 (CXCL5), Eotaxin (CCL11), Eotaxin-2 (CCL24), Eotaxin-3 (CCL26), FGF-2, Flt-3 Ligand, Fractalkine (CX3CL1), G-CSF, GCP-2 (CXCL6), GM-CSF, Granzyme A, Granzyme B, GROα (CXCL1), HMGB1, I-309 (CCL1), IFNα2, IFNβ, IFNγ, IFNω, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17E/IL-25, IL-17F, IL-18, IL-20, IL-21, IL-22, IL-23, IL-24, IL-27, IL-28A (IFNλ2), IL-29 (IFNλ1), IL-31, IL-33, IL-34, IL-35, IP-10 (CXCL10), I-TAC (CXCL11), LIF, Lymphotactin (XCL1), MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7), MCP-4 (CCL13), M-CSF, MDC (CCL22), MIG (CXCL9), MIP-1α (CCL3), MIP-1β (CCL4), MIP-1δ (CCL15), MIP-3α (CCL20), MIP-3β (CCL19), MPIF-1 (CCL23), PDGF-AA, PDGF-AB/BB, Perforin, RANTES (CCL5), sCD40L, sCD137, SCF, SDF-1 (CXCL12), sFas, sFasL, TARC (CCL17), TGFα, TNFα, TNFβ (LTα), TPO, TRAIL, TSLP, VEGF-A
TURNAROUND-TIME (TAT)
1-5 Days
SAMPLE STABILITY
Samples collected for immune-related biomarkers are stable for approximately 1 year if kept frozen (-80˚C preferred). Samples that are left at room temperature beyond 30 minutes during sample collection or are stored at 4˚C are not stable and are not acceptable unless they are processed in BD P-100 tubes.
PROCEDURE / TECHNIQUE
Luminex® 100/200 (Addressable LASER Bead Immunoassay)
REFERENCE RANGE
Available for plasma-EDTA, serum, and CSF. See example reports below
CLINICAL ASSOCIATIONS
Eve Diagnostics’ comprehensive cytokine panel provides an in-depth profile of the circulating immune microenvironment underlying the clinical presentation of acute and chronic inflammatory conditions, autoimmune, and autoinflammatory diseases.
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with immune regulation, inflammation, and cell signaling:
- Autoimmune and Inflammatory Diseases: Assess a wide range of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, and inflammatory bowel disease (IBD).
- Infectious Diseases: Evaluate the immune response to bacterial, viral, and fungal infections.
- Cancer: Monitor tumor progression and response to therapy in various cancers, assessing cytokines that are involved in tumor growth, angiogenesis, and immune evasion.
- Allergic and Asthma Conditions: Diagnose and monitor allergic diseases and asthma, where type 2 cytokines play pivotal roles in mediating allergic inflammation and airway hyperreactivity.
- Cardiovascular Diseases: Assess cardiovascular health, including atherosclerosis and heart failure, assessing biomarkers indicating vascular inflammation and remodeling.
- Metabolic and Obesity-Related Disorders: Investigate the role of inflammation in metabolic syndrome, diabetes, and obesity.
- Neurological Disorders: Monitor neuroinflammatory conditions such as multiple sclerosis, Alzheimer’s disease, and neuropathic pain, assessing cytokine profiles indicating neuroinflammation and neuronal damage.
- Bone and Joint Disorders: Evaluate bone and joint diseases such as osteoarthritis and osteoporosis, where the cytokine profile can indicate inflammatory and catabolic processes affecting bone and cartilage.
Results are presented with clusters of co-expressing cytokines identified with unsupervised clustering analyses of >130 plasma-EDTA specimens provided to us for diagnostic testing from patients with a variety of inflammatory, autoimmune, and neoplastic conditions, using a similar methodology as detailed in our publication(Polley et al. Front Immunol 2023). Detailed descriptions of the cytokine groupings provided in the test results can be found here.
Detailed analysis provides insights into immune activation patterns and physiological characteristics underlying patient clinical presentations. Cytokine expression patterns in the results are assessed to provide evidence for the type(s)of immunity underlying the patient’s inflammatory response (type 1/Th1-type, type 2/Th2-type, and type 3/Th17-type immunity), along with other features of the inflammatory response (lymphocyte expansion/activation, leukocyte involvement).
The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Cytokine levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.
Find example reports with distinct immune activation profiles as visualized with the cytokine clusters below.
Example report – Abnormal Plasma – Autoinflammatory syndrome
Example report – Abnormal Plasma – HLH
Example report – Abnormal Plasma – Systemic arthritis/MAS
Example report – Abnormal Serum -FIRES
Example report – Abnormal Serum – Long COVID